Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

LifeCodexx Expands its PraenaTest® Spectrum

Published: Saturday, June 28, 2014
Last Updated: Saturday, June 28, 2014
Bookmark and Share
Additional PraenaTest® options for the exclusive determination of fetal trisomy 21 and gonosomal aneuploidy now available.

PraenaTest®, Europe‘s first non-invasive molecular genetic prenatal diagnostic test (NIPT) to determine fetal chromosome disorders from maternal blood, now comprises two additional test options.

One new option allows physicians to add the determination of fetal gonosomal aneuploidy for singleton pregnancies, such as Turner, Triple X, Klinefelter and XYY syndrome, to the standard analysis of fetal trisomies 21, 18 and 13.

The second new option exclusively determines trisomy 21 in the unborn child. Therefore, depending on the medical issue, physicians and their patients can now select from a total range of three PraenaTest® options for singleton and multiple pregnancies with an average waiting time for the test results of eight working days or even four working days, if express service is selected.

“The new PraenaTest® portfolio strengthens the physicians’ competence to decide which chromosomal disorders are to be determined. Now they can adapt the genetic examination according to the patient’s individual needs,“ says Dr. Michael Lutz, CEO of LifeCodexx AG.

Following LifeCodexx´ application to the Federal Joint Committee of Germany (G-BA) in 2013, the company recently received a positive decision concerning statutory health insurance coverage for the PraenaTest® analysis costs through a novel reimbursement scheme (“Erprobungsregelung”) in Germany.

Starting 2015, this scheme will allow patients to be refunded by their statutory health insurances for a trial period during which a reimbursement-driven clinical validation will be performed.

PraenaTest® was selected by the committee for this study as it strictly complies with the high quality standards in accordance with the European In Vitro Diagnostic Directive and due to its use of the CE-marked data analysis software as a medical device.

A new study regarding the validation of the PraenaTest® in multiple pregnancies and the impact of vanishing twins in NIPT has recently been accepted by the Journal of Clinical Medicine for publication. It is the second peer-reviewed publication regarding the clinical validation of the PraenaTest® in singleton and multiple pregnancies.

To date, more than 11,000 women have opted for PraenaTest®. Several statutory as well as private health insurance funds in several countries already cover the costs for the analysis on individual basis.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

LifeCodexx Reports Successful Proof-of-Principle of Innovative PCR-based NIPT Assay
Breakthrough potential as affordable NIPT solution on global basis.
Friday, April 03, 2015
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!